These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2532556)

  • 21. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.
    Yang H; Zong X; Yu Y; Shao G; Zhang L; Qian C; Bian Y; Xu X; Sun W; Meng X; Ding X; Chen D; Zou D; Xie S; Zheng Y; Zhang J; He X; Sun C; Yu X; Ni J
    Br J Cancer; 2013 Aug; 109(3):582-8. PubMed ID: 23860520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
    Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
    Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
    Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
    J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoladex: therapeutic effects in postmenopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival.
    Dixon AR; Jackson L; Robertson JF; Nicholson RI; Blamey RW
    Eur J Cancer; 1991; 27(6):806-7. PubMed ID: 1829930
    [No Abstract]   [Full Text] [Related]  

  • 27. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.
    Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R
    J Natl Cancer Inst; 2009 Mar; 101(5):341-9. PubMed ID: 19244174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
    Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
    Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
    Takuwa H; Saji S; Takada M; Takahara S; Yamauchi A
    Breast Dis; 2018; 37(4):185-190. PubMed ID: 29578459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study.
    Berglund G; Nystedt M; Bolund C; Sjödén PO; Rutquist LE
    J Clin Oncol; 2001 Jun; 19(11):2788-96. PubMed ID: 11387349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
    Klijn JG; de Jong FH; Blankenstein MA; Docter R; Alexieva-Figusch J; Blonk-van der Wijst J; Lamberts SW
    Breast Cancer Res Treat; 1984; 4(3):209-20. PubMed ID: 6435703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
    Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
    Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.
    Jonat W
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S23-6: discussion S33-5. PubMed ID: 12353820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
    Matta WH; Shaw RW; Burford GD
    Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.